title: [Efficacy of voriconazole treatment in chronic vulvovaginal candidosis due to Candida glabrata].
abstract: BACKGROUND
  Vulvovaginal candidosis is a common infection in young women, and it is associated with high morbidity and high health costs.
  
  
  OBJECTIVE
  Vulvovaginal candidosis caused by Candida glabrata is a therapeutic challenge due to the acquired resistance of many strains of this species to azole antifungals.
  
  
  METHODS
  We present two cases of vaginal candidosis complicated by fluconazole-resistant Candida glabrata, and treated with voriconazole.
  
  
  RESULTS
  Both patients improved after administration of voriconazole, 400 mg/12 h the first day and then 200 mg every 12 h for 14 days. Their symptoms disappeared and cultures became negative.
  
  
  CONCLUSIONS
  These results suggest voriconazole can be used as a therapeutic alternative for this type of candidosis which, although not life threatening, is associated with a high morbidity.
authors.affiliation: Servicio de Dermatología, Hospital Carlos Haya, Málaga, España. eligm80@hotmail.com
authors.forename: Elisabeth
authors.initials: E
authors.lastname: Gomez-Moyano
authors.forename: Ana
authors.initials: A
authors.lastname: Cid Lama
authors.forename: Maria Dolores
authors.initials: MD
authors.lastname: Fernández Ballesteros
authors.forename: Miguel
authors.initials: M
authors.lastname: Lova Navarro
authors.forename: Angel
authors.initials: A
authors.lastname: Vera Casaño
authors.forename: Vicente
authors.initials: V
authors.lastname: Crespo Erchiga
mesh_terms: D000328:Adult; D000935:Antifungal Agents / Q000494:pharmacology / Q000627:therapeutic use*; D041221:Candida glabrata / Q000187:drug effects* / Q000302:isolation & purification; D002181:Candidiasis, Vulvovaginal / Q000188:drug therapy* / Q000382:microbiology; D002585:Cesarean Section; D004341:Drug Evaluation; D026141:Drug Resistance, Multiple, Fungal; D005260:Female; D015725:Fluconazole / Q000494:pharmacology; D006801:Humans; D008826:Microbial Sensitivity Tests; D011247:Pregnancy; D011644:Puerperal Disorders / Q000188:drug therapy / Q000382:microbiology; D011743:Pyrimidines / Q000494:pharmacology / Q000627:therapeutic use*; D012008:Recurrence; D013045:Species Specificity; D016896:Treatment Outcome; D014230:Triazoles / Q000494:pharmacology / Q000627:therapeutic use*; D065819:Voriconazole; D055815:Young Adult
chemical_list: D000935:Antifungal Agents; D011743:Pyrimidines; D014230:Triazoles; D015725:Fluconazole; D065819:Voriconazole